Eloralintide (5mg)

What is Eloralintide?

Eloralintide is a catalog research material in the glp-1 & metabolic category. The listed strengths describe total vial contents for laboratory research.

Listed vial contents: 5mg. These are supplied quantities, not administration doses. Current pricing and availability are shown in the strength selector.

What mechanisms are being studied?

Eloralintide (LY3841136) is a long-acting amylin-receptor agonist developed by Eli Lilly. Like other long-acting amylin analogs it engages the amylin / calcitonin receptor complexes in the hypothalamus and area postrema to drive satiety, gastric-emptying delay, and post-prandial glucagon suppression. Lilly is developing eloralintide both as monotherapy and as a fixed-dose combination with retatrutide-class molecules.

What are the research questions?

• Obesity research: Phase 1 dose-finding reported clinically relevant weight loss across multi-week dosing windows with a favorable tolerability profile.
• Amylin / incretin combination research: Studied as a Lilly-internal pairing partner with GLP-1 / GIP / glucagon triple agonists to test additivity vs incretin monotherapy.
• Selectivity comparator: Used in pharmacology studies comparing selective amylin agonism vs dual amylin / calcitonin agonism on weight, glycemia, and GI signaling.
• Mechanism research: One of only a handful of selective amylin tool molecules available for in-vivo pharmacology research.

What does the published work describe?

Eli Lilly Phase 1 disclosures (2024) established dose-dependent weight loss over 12 weeks in adults with obesity. Phase 2 obesity program initiated 2024; combination Phase 2 with retatrutide-class compounds announced 2025.

What are the limits of this evidence?

The research described concerns the cited experimental materials and models, not proof that this supplied vial is a treatment. Cell or animal findings do not establish human benefits. Clinical findings, where cited, apply to the tested formulation and population; they do not validate this research product for human use.

Study references

1. Eli Lilly Eloralintide Phase 1 disclosure, 2024
2. Eli Lilly Phase 2 obesity & combination announcement, 2025
3. Lutz TA. Physiol Behav 2010 — amylin pharmacology

These are the catalog's existing bibliographic references. No new source verification is implied by this presentation.

How should I check lot documentation?

Match the product, strength and lot to an original analysis document. Literature describes experimental findings; it does not verify the contents of this inventory. Generated sample reports illustrate the reporting flow and are not evidence of testing, purity or accreditation.